Preferences for Tapering Biologic Disease-Modifying Antirheumatic Drugs Among People With Rheumatoid Arthritis: A Discrete Choice Experiment

Overview

Journal Arthritis Care Res (Hoboken)

Specialty Rheumatology

Date 2024 Sep 23

PMID 39308004

Authors

Suz Jack Chan

Lisa K Stamp

Gareth J Treharne

Janet M Y Cheung

Nicola Dalbeth

Rebecca Grainger

Simon Stebbings

Carlo A Marra

Affiliations

Soon will be listed here.

Abstract

Objective: Little is known about the preferences of people with rheumatoid arthritis (RA) regarding tapering of biologic disease-modifying antirheumatic drugs (bDMARDs). The aim of this study was to assess the preferences of people with RA in relation to potential treatment-related benefits and risks of bDMARD tapering and the health care service-related attributes that affect tapering.

Methods: Participants with RA who had experience taking a bDMARD completed an online discrete choice experiment. Participants were asked their preferences when given three hypothetical treatment scenarios in which varying the frequency of treatment might alter their chance of adverse effects, of regaining disease control, and of other health care service-related effects. Preference weights were estimated using a multinomial logit model.

Results: There were 142 complete responses. Reduced dosing frequency of bDMARD treatment had the largest impact on preference (mean 1.0, 95% confidence interval [CI] 0.8-1.2), followed by chance of disease flare (mean 0.7, 95% CI 0.6-0.9). Participants were willing to accept an increased risk of flare between 10.6% (95% CI 3.2-17.9) and 60.6% (95% CI 48.1-72.9) in exchange for benefits associated with tapering bDMARDs. Participants with better quality of life were more likely to choose to remain on current treatment. The predicted uptake of bDMARD tapering was high among people with RA, suggesting bDMARD tapering was a favored option.

Conclusion: For individuals with RA, making decisions about tapering bDMARDs involves considering several factors, with the most important determinants identified as dosing frequency and the risk of disease flare. Understanding patient perspectives of bDMARD tapering may enable physicians to make patient-focused shared health care decisions.

References

Fagerlin A, Zikmund-Fisher B, Ubel P, Jankovic A, Derry H, Smith D . Measuring numeracy without a math test: development of the Subjective Numeracy Scale. Med Decis Making. 2007; 27(5):672-80. DOI: 10.1177/0272989X07304449. View

Bridges J, Mohamed A, Finnern H, Woehl A, Hauber A . Patients' preferences for treatment outcomes for advanced non-small cell lung cancer: a conjoint analysis. Lung Cancer. 2012; 77(1):224-31. DOI: 10.1016/j.lungcan.2012.01.016. View

Bridges J, Hauber A, Marshall D, Lloyd A, Prosser L, Regier D . Conjoint analysis applications in health--a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value Health. 2011; 14(4):403-13. DOI: 10.1016/j.jval.2010.11.013. View

Hurst N, Jobanputra P, Hunter M, Lambert M, Lochhead A, Brown H . Validity of Euroqol--a generic health status instrument--in patients with rheumatoid arthritis. Economic and Health Outcomes Research Group. Br J Rheumatol. 1994; 33(7):655-62. DOI: 10.1093/rheumatology/33.7.655. View

Smolen J, Aletaha D, Bijlsma J, Breedveld F, Boumpas D, Burmester G . Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010; 69(4):631-7. PMC: 3015099. DOI: 10.1136/ard.2009.123919. View

Gunther O, Kurstein B, Riedel-Heller S, Konig H . The role of monetary and nonmonetary incentives on the choice of practice establishment: a stated preference study of young physicians in Germany. Health Serv Res. 2009; 45(1):212-29. PMC: 2813445. DOI: 10.1111/j.1475-6773.2009.01045.x. View

Poulos C, Hauber A, Gonzalez J, Turpcu A . Patients' willingness to trade off between the duration and frequency of rheumatoid arthritis treatments. Arthritis Care Res (Hoboken). 2013; 66(7):1008-15. DOI: 10.1002/acr.22265. View

Heidenreich S, Phillips-Beyer A, Flamion B, Ross M, Seo J, Marsh K . Benefit-Risk or Risk-Benefit Trade-Offs? Another Look at Attribute Ordering Effects in a Pilot Choice Experiment. Patient. 2020; 14(1):65-74. DOI: 10.1007/s40271-020-00475-y. View

Jonker M, Donkers B, De Bekker-Grob E, Stolk E . Attribute level overlap (and color coding) can reduce task complexity, improve choice consistency, and decrease the dropout rate in discrete choice experiments. Health Econ. 2018; 28(3):350-363. PMC: 6590347. DOI: 10.1002/hec.3846. View

10.

Treharne G, Johnstone G, Fletcher B, Lamar R, White D, Stebbings S . Fears about COVID-19 and perceived risk among people with rheumatoid arthritis or ankylosing spondylitis following the initial lockdown in Aotearoa New Zealand. Musculoskeletal Care. 2021; 20(2):290-298. PMC: 8441895. DOI: 10.1002/msc.1585. View

11.

Husni M, Betts K, Griffith J, Song Y, Ganguli A . Benefit-risk trade-offs for treatment decisions in moderate-to-severe rheumatoid arthritis: focus on the patient perspective. Rheumatol Int. 2017; 37(9):1423-1434. DOI: 10.1007/s00296-017-3760-z. View

12.

Hauber A, Gonzalez J, Groothuis-Oudshoorn C, Prior T, Marshall D, Cunningham C . Statistical Methods for the Analysis of Discrete Choice Experiments: A Report of the ISPOR Conjoint Analysis Good Research Practices Task Force. Value Health. 2016; 19(4):300-15. DOI: 10.1016/j.jval.2016.04.004. View

13.

Hewlett S, Haig-Ferguson A, Rose-Parfitt E, Halls S, Freke S, Creamer P . Dose reduction of biologic therapy in inflammatory arthritis: A qualitative study of patients' perceptions and needs. Musculoskeletal Care. 2018; 17(1):63-71. DOI: 10.1002/msc.1367. View

14.

Johnstone G, Treharne G, Fletcher B, Lamar R, White D, Harrison A . Mental health and quality of life for people with rheumatoid arthritis or ankylosing spondylitis in Aotearoa New Zealand following the COVID-19 national lockdown. Rheumatol Int. 2021; 41(10):1763-1772. PMC: 8298198. DOI: 10.1007/s00296-021-04952-x. View

15.

Louder A, Singh A, Saverno K, Cappelleri J, Aten A, Koenig A . Patient Preferences Regarding Rheumatoid Arthritis Therapies: A Conjoint Analysis. Am Health Drug Benefits. 2016; 9(2):84-93. PMC: 4856233. View

16.

Bertrand D, Stouten V, De Cock D, Pazmino S, Doumen M, de Wergifosse I . Tapering of Etanercept is feasible in patients with Rheumatoid Arthritis in sustained remission: a pragmatic randomized controlled trial. Scand J Rheumatol. 2021; 51(6):470-480. DOI: 10.1080/03009742.2021.1955467. View

17.

Verhoef L, van den Bemt B, van der Maas A, Vriezekolk J, Hulscher M, van den Hoogen F . Down-titration and discontinuation strategies of tumour necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity. Cochrane Database Syst Rev. 2019; 5:CD010455. PMC: 6534285. DOI: 10.1002/14651858.CD010455.pub3. View

18.

Chan S, Yeo H, Stamp L, Treharne G, Marra C . What Are the Preferences of Patients With Rheumatoid Arthritis for Treatment Modification? A Scoping Review. Patient. 2020; 14(5):505-532. DOI: 10.1007/s40271-020-00488-7. View

19.

Wallis D, Holmes C, Holroyd C, Sonpal K, Zarroug J, Adams J . Dose reduction of biological therapies for inflammatory rheumatic diseases: what do patients think?. Scand J Rheumatol. 2018; 48(3):251-252. DOI: 10.1080/03009742.2018.1533034. View

20.

Smolen J, Landewe R, Bergstra S, Kerschbaumer A, Sepriano A, Aletaha D . EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2022; 82(1):3-18. DOI: 10.1136/ard-2022-223356. View